Medicare tightens telehealth rules for expensive equipment and tests

What it does

This bill restricts Medicare payment for high-cost durable medical equipment and laboratory tests ordered via telehealth unless the prescribing physician has seen the patient in person within the prior 6 months. It requires CMS to define what qualifies as 'high-cost,' mandates audits of providers who prescribe such items via telehealth more than 90% of the time, and requires providers to submit their National Provider Identification number for telehealth billing. The stated goal is to prevent fraud and inappropriate telehealth utilization in Medicare.

Why we flagged it

The bill directly targets telehealth-prescribed durable medical equipment and laboratory tests by imposing in-person visit requirements and audit mechanisms. Its functional purpose is to reduce Medicare fraud and inappropriate telehealth utilization, not to benefit a specific industry or officeholder.

What the text implies

• The 180-day implementation window and 6-month lookback period may create a transition period during which providers adjust billing practices, potentially reducing telehealth utilization for high-cost items even before enforcement begins.
• The 90-percent threshold for identifying high-volume telehealth prescribers may disproportionately flag legitimate telehealth practitioners in rural or underserved areas where in-person visits are logistically difficult, potentially reducing access to care.

The full analysis lists 5 implications of this text.

Who stands to gain

Medicare program (reduced fraud/improper payments); Durable medical equipment suppliers (reduced competition from telehealth-driven over-prescription); In-person medical practices (increased demand for in-person visits)